AMANDA LIVELY: Open Payments
NPI 1982064622 · PRICE, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 42 payments from 20 companies in 2025. Trend: 2023 $603 · 2024 $578 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $265 |
| AstraZeneca Pharmaceuticals LP | 5 | $93 |
| PFIZER INC. | 3 | $56 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $55 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Biogen, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $26 |
| SANOFI-AVENTIS U.S. LLC | 1 | $26 |
| Organon LLC | 1 | $25 |
Products named: VRAYLAR, UBRELVY, REXULTI, AIRSUPRA, Kerendia, Qelbree, QULIPTA, SKYCLARYS.
Industry payments across UT — which companies pay providers there.
